Sugi Predict

Sugi Predict / Compounds / SCHEMBL371810

SCHEMBL371810

SCHEMBL371810

COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)c(C)n3)c2cc1OC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 15/20 0.73
▸ MET P08581 10/20 0.73
▸ MERTK Q12866 6/20 0.73
▸ KDR P35968 3/20 0.73
▸ FLT1 P17948 2/20 0.73
▸ AURKB Q96GD4 2/20 0.73
▸ AURKA O14965 1/20 0.73
▸ RIPK2 O43353 1/20 0.73
▸ ABCB11 O95342 1/20 0.73
▸ ABL1 P00519 1/20 0.73
▸ EGFR P00533 1/20 0.73
▸ ERBB2 P04626 1/20 0.73
▸ NTRK1 P04629 1/20 0.73
▸ LCK P06239 1/20 0.73
▸ PGR P06401 1/20 0.73
▸ LYN P07948 1/20 0.73
▸ RET P07949 1/20 0.73
▸ CHRM2 P08172 1/20 0.73
▸ HCK P08631 1/20 0.73
▸ ADRA2A P08913 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693454 1.00 AXL (0.73) AXLMETMERTKKDRFLT1
SCHEMBL24444598 0.93 AXL (0.63) AXLMETMERTKKDRFLT1
SCHEMBL15765565 0.89 MET (0.69) AXLMETMERTKKDRFLT1
SCHEMBL12829250 0.88 AXL (0.73) AXLMETMERTKKDRFLT1
SCHEMBL371732 0.88 MET (0.80) AXLMETMERTKKDRFLT1
SCHEMBL30537415 0.88 AXL (0.81) AXLMETMERTKKDRFLT1
SCHEMBL22949515 0.88 AXL (0.81) AXLMETMERTKKDRFLT1
SCHEMBL29693421 0.88 AXL (0.72) AXLMETMERTKKDRFLT1
SCHEMBL371962 0.88 AXL (0.72) AXLMETMERTKKDRFLT1
SCHEMBL5143531 0.86 AXL (0.76) AXLMETMERTKKDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP claimed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20120022065-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-01-26 — — US claimed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 — — EP claimed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MET 3/4885MERTK 17/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET AXL 109/4885MET 3/4885MERTK 17/4885
US-20120022065-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 AXL 241/4885MET 2/4885MERTK 23/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MET 3/4885MERTK 17/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET AXL 109/4885MET 3/4885MERTK 17/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET AXL 109/4885MET 3/4885MERTK 17/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 AXL 241/4885MET 2/4885MERTK 23/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 AXL 241/4885MET 2/4885MERTK 23/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET AXL 109/4885MET 3/4885MERTK 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.